ReviewJournal of cachexia, sarcopenia and muscle2017
Curcumin: An effective adjunct in patients with statin-associated muscle symptoms?
Review in Journal of cachexia, sarcopenia and muscle, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 70 citations in OpenAlex.
- Targeting NLRP3 inflammasome with curcumin: mechanisms and therapeutic promise in chronic inflammation.Inflammopharmacology · 2025Review
- Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review.Journal of advanced research · 2025Review
- Therapeutic potential of clinically proven natural products in the management of dementia.Heliyon · 2024Review
- Curcumin-Based Fixed Dose Combination Products for Cholesterol Management: A Narrative Review.ACS pharmacology & translational science · 2024Review
- The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper.Archives of medical science : AMS · 2023Article
- Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?Frontiers in nutrition · 2022Review
- Pairing 3D-Printing with Nanotechnology to Manage Metabolic Syndrome.International journal of nanomedicine · 2022Article
- Curcumin-Loaded Hydrophobic Surface-Modified Hydroxyapatite as an Antioxidant for Sarcopenia Prevention.Antioxidants (Basel, Switzerland) · 2021Article
- Curcumin: A Review of Its Effects on Epilepsy.Advances in experimental medicine and biology · 2021Review
- Pathophysiological mechanisms of statin-associated myopathies: possible role of the ubiquitin-proteasome system.Journal of cachexia, sarcopenia and muscle · 2020Review
- The difference in referencing in Web of Science, Scopus, and Google Scholar.ESC heart failure · 2019Article
- The Journal of Cachexia, Sarcopenia and Muscle stays the front-runner in geriatrics and gerontology.Journal of cachexia, sarcopenia and muscle · 2019Article
- Sarcopenia disease in Iran: an overview.Journal of diabetes and metabolic disorders · 2019Review
- The role of curcumin in liver diseases.Archives of medical science : AMS · 2019Article
- Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management.Pharmaceutical medicine · 2019Review
- Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis.International journal of nanomedicine · 2019Article
- Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018.Journal of cachexia, sarcopenia and muscle · 2018Article
- Management of Statin Intolerance in 2018: Still More Questions Than Answers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2018Review
- Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.Clinical cardiology · 2018Review
- Methylglyoxal and Advanced Glycation End products: Insight of the regulatory machinery affecting the myogenic program and of its modulation by natural compounds.Scientific reports · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of the unequivocal efficacy of statins in reducing primary and secondary cardiovascular events, the use of these drugs in a considerable number of patients is limited because of statin intolerance, mainly statin-associated muscle symptoms (SAMS). SAMS encompass a broad spectrum of clinical presentations, including mild muscular aching and other types of myalgias, myopathy with the significant elevation of creatine kinase, and the rare but life-threatening rhabdomyolysis. Among several pathophysiologic mechanisms of SAMS, mitochondrial dysfunction is thought to be one of the main one. Curcumin is the polyphenolic ingredient of Curcuma longa L., which has various pharmacological properties against a vast range of diseases. Curcumin has several mechanisms of actions relevant to the treatment of SAMS. These effects include the capacity to prevent and reduce delayed onset muscle soreness by blocking the nuclear factor inflammatory pathway, attenuation of muscular atrophy, enhancement of muscle fibre regeneration following injury, and analgesic and antioxidant effects. Curcumin can also increase the levels of cyclic adenosine monophosphate, which leads to an increase in the number of mitochondrial DNA duplicates in skeletal muscle cells. Finally, owing to its essential lipid-modifying properties, curcumin might serve as an adjunct to statin therapy in patients with SAMS, allowing for effective lowering of low-density lipoprotein cholesterol and possibly for statin dose reduction. Owing to the paucity of effective treatments, and the safety of curcumin in clinical practice, proof-of-concept trials are recommended to assess the potential benefit of this phytochemical in the treatment of SAMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.